1 Min Read
May 17 (Reuters) - Eiger Biopharmaceuticals Inc
* Eiger announces results demonstrating benefit of ubenimex and leukotriene B4 (LTB4) modulation in experimental lymphedema Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.